Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution

0Citations
Citations of this article
72Readers
Mendeley users who have this article in their library.

Abstract

The apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) mutational signature has only recently been detected in a multitude of cancers through next-generation sequencing. In contrast, APOBEC has been a focus of virology research for over a decade. Many lessons learnt regarding APOBEC within virology are likely to be applicable to cancer. In this review, we explore the parallels between the role of APOBEC enzymes in HIV and cancer evolution. We discuss data supporting the role of APOBEC mutagenesis in creating HIV genome heterogeneity, drug resistance, and immune escape variants. We hypothesize similar functions of APOBEC will also hold true in cancer.

Cite

CITATION STYLE

APA

Venkatesan, S., Rosenthal, R., Kanu, N., McGranahan, N., Bartek, J., Quezada, S. A., … Swanton, C. (2018, March 1). Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Annals of Oncology. Oxford University Press. https://doi.org/10.1093/annonc/mdy003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free